Immuno Lab · Cure for X

Cure for Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency

PatSci's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency — screening already-approved drugs against its 4-gene Open Targets disease module to file a DAO-owned patent. Research is fast; the filing path is funded in milestone stages.

Disease module4 genesLead labImmuno

All cures

ImmunoDOID:5810$PatSciImmuno

The science

Disease moduleSevere combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency maps to a 4-gene Open Targets module — the target space PatSci's AI scientist screens approved drugs against.

PatSci.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces PatSci.ai's repurposing hypotheses.

Repurposing thesisScreening already-approved drugs against this module — then filing a new-use patent on the most promising candidate. Known safety profiles make the path faster and cheaper than de-novo discovery.

The patent path

Priority€50K

Candidate research + dossier + UK patent deposit (priority date, prior-art scan).Month 0 · proof: UKIPO application number + on-chain hash

Validation€150K

In-vitro biological validation at a contract research org (CRO).Months 1–10 · proof: CRO contract + in-vitro report

PCT Global€600K

International PCT filing across 150+ countries.by Month 12 · proof: PCT application number

National€200K

National / regional phases (EU, US, CN).by Month 30 · proof: National grant confirmations

PatSci is a research and patent-filing project, not medical advice and not a treatment. "Cure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund patent work — it is not an investment, and confers no yield, royalty, equity or patent ownership. Patents are owned by the PatSci.ai DAO Patent Estate.